References
- Lindsay R, Hart DM. Effect of oestrogens on postmenopausal bone loss. Br Med J 1977;2:1087
- Aitken JM, Hart DM, Lindsay R. Oestrogen replacement therapy for the prevention of osteoporosis after oophorectomy. Br Med J 1973;3:515–18
- The Writing Group for the PEPI. Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 1996;276:1389–96
- Black DM, Cummings SR, Karpf DB, et al. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535–41
- Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999;282:1344–52
- Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434–41
- Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321–33
- Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA 2003;290: 1729–38
- Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350:459–68
- Cummings SR, Ettinger B, Delmas PD, et al. The effects of tibolone in older postmenopausal women. N Engl J Med 2008; 359:697–708
- Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809–22
- Silverman SL, Christiansen C, Genant HK, et al. Efficacy of bazedoxifene in reducing new vertebral fracture rate in postmenopausal women with osteoporosis: results of a 3-year randomized, placebo- and active-controlled clinical trial. J Bone Miner Res 2008;12:1923–34
- Cummings SR, Martin JS, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361:756–65
- Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA 2013;310:1353–68
- Pickar JH, Mirkin S. Tissue-selective agents: selective estrogen receptor modulators and the tissue-selective estrogen complex. Menopause Int 2010;16:121–8
- Riggs BL. The mechanism of estrogen regulation of bone resorption. J Clin Invest 2000;106:1203–4
- Shapiro S, De Villiers TJ, Pines A, et al. Risks and benefits of hormone therapy: has medical dogma now been overturned? Climacteric 2014;17:215–22
- De Villiers TJ, Stevenson JC. The WHI: the effect of hormone replacement therapy on fracture prevention. Climacteric 2012; 15:263–6
- European Medicines Agency. EMA/258269/2013
- De Villiers TJ, Gass MLS, Haines CJ, et al. Global Consensus Statement on Menopausal Hormone Therapy. Climacteric 2013;16:203–4